Gábor Gyülvészi

Gábor Gyülvészi joined Seed Investments as Principal in May 2025.

Before joining Novo Holdings, Gábor was Chief Business Officer at Centenara Labs. Prior to that, he was a Venture Investor at Nextech Invest. He began his industry career as Lab Head and Principal Scientist in cancer immunotherapy in F. Hoffmann-La Roche. 

Gábor currently chairs the boards of Akylox and Engimmune Therapeutics and serves as a board director at RefuelBio, deNovo Foundry, and RheumaLogics.

Gábor holds a PhD in Experimental Immunology from the University of Zurich. He completed his postdoctoral research at the Institute for Research in Biomedicine in Bellinzona. He has published extensively in the field of immunology and received the Biogen Dompé Award in Autoimmunity.